Clinical Trials Browser

Completed × Interventional × Afatinib × Clear all

NCT02979977 2026-02-04

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Phase 2 Completed

50 enrolled 14 charts

Squamous Cell Cancers of the Head and Neck

NCT01856478 2026-01-12

LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Phase 3 Completed

340 enrolled 23 charts

Head and Neck Neoplasms

NCT06494189 2025-12-29

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

Phase 1 Completed

Head and Neck Neoplasms

NCT07271446 2025-12-09

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT05517330 2025-07-31

neoCHANCE-1

Phase 2 Completed

Head and Neck Neoplasms

NCT02191891 2025-06-25

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

32 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT05516589 2025-05-22

neoCHANCE-2

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01783587 2025-05-01

Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT02597946 2025-02-19

Afatinib in NSCLC With HER2 Mutation

Phase 2 Completed

18 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT01649271 2025-02-11

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

Phase 1 Completed

13 enrolled 11 charts

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT00950742 2025-02-10

Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

Phase 1 Completed

18 enrolled 14 charts

Breast Neoplasms

NCT01214616 2025-02-07

BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours

Phase 1 Completed

17 enrolled 15 charts

Neoplasms

NCT02171650 2025-01-23

BIBW 2992 in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT02364609 2024-10-16

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Phase 1 Completed

11 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT04839471 2024-07-08

BEAR

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04410653 2024-04-05

Afatinib in Advanced NRG1-Rearranged Malignancies

Phase 2 Completed

Neoplasm Metastasis

NCT01542437 2024-02-06

NSCLC

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2 Completed

100 enrolled 14 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT02183883 2023-11-29

DARWIN1

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01522768 2023-11-01

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

Phase 2 Completed

42 enrolled 9 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT03727724 2023-10-18

AFACET

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02506517 2023-08-01

A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene

Phase 2 Completed

Other solid neoplasm

Solid Tumors

NCT02501603 2023-01-27

Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT04201756 2022-12-23

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

Phase 2 Completed

Adenocarcinoma of Lung

NCT02716311 2022-08-11

ACE-Lung

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02451553 2022-06-07

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

Phase 1 Completed

Gastrointestinal

Bile Duct Neoplasms, Pancreatic Neoplasms

NCT03695510 2022-04-21

ALPHA

Phase 2 Completed

Head and Neck Neoplasms

NCT01156545 2022-04-06

BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02423525 2022-03-10

Safety Study of Afatinib for Brain Cancer

Phase 1 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Meningioma, Oligodendroglioma, Meningeal Carcinomatosis

NCT01415674 2022-02-02

PREDICTOR

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT02629523 2021-08-03

LiquidLung-A

Phase 2 Completed

Lung Neoplasms

NCT01427478 2021-06-01

BIBW2992ORL

Phase 3 Completed

Squamous Cell Carcinoma of Head and Neck

NCT02372006 2021-03-04

Trial of Afatinib in Pediatric Tumours

Phase 1/2 Completed

56 enrolled 23 charts

Rhabdomyosarcoma, Neuroectodermal Tumors

NCT01999985 2020-11-27

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

25 enrolled 10 charts

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Pleural Diseases, Pleural Effusion, Pleural Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Pleural Effusion, Malignant

NCT02780687 2020-11-18

LUX-Bladder 1

Phase 2 Completed

42 enrolled 16 charts

Urologic Neoplasms

NCT01466660 2020-04-07

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Phase 2 Completed

319 enrolled 19 charts

Lung Neoplasms

NCT02514174 2020-03-30

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Phase 4 Completed

25 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT01953913 2019-08-12

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

Phase 3 Completed

542 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT01125566 2019-07-18

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Phase 3 Completed

508 enrolled 13 charts

Breast Neoplasms

NCT02145637 2019-03-29

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

Lung Neoplasms, Neoplasms

NCT02142036 2019-03-13

MetAction

Phase 2 Completed

Neoplasm Metastasis

NCT00977431 2019-02-18

Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform

Phase 1 Completed

36 enrolled 16 charts

Glioblastoma

NCT01523587 2019-02-15

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Phase 3 Completed

795 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT01206816 2019-02-01

An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours

Phase 1 Completed

57 enrolled 19 charts

Neoplasms

NCT01415011 2019-01-15

TIMELY

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02208843 2018-12-17

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Phase 4 Completed

60 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT01121393 2018-12-14

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Phase 3 Completed

364 enrolled 28 charts 1 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT01538381 2018-07-09

Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT01919879 2018-05-08

Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT00949650 2018-04-06

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Phase 3 Completed

345 enrolled 23 charts 1 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung